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ABSTRACT
Objective: Tumor necrosis factor-inducible gene 6 (TSG-6) has anti-inflammatory
and chondroprotective effects in mouse models of inflammatory arthritis. Because
cartilage damage and inflammation are also observed in osteoarthritis (OA), we
determined the effect of viral overexpression of TSG-6 in experimental
osteoarthritis.
Methods: Bone marrow-derived cells were differentiated to multinucleated
osteoclasts in the presence of recombinant TSG-6 or after transduction with a
lentiviral TSG-6 expression vector. Multi-nucleated osteoclasts were analyzed
after tartrate resistant acid phosphatase staining and resorption activity was
determined on dentin slices. Collagenase-induced osteoarthritis (CIOA) was
induced in C57BL/6 mice after intra-articular injection of an adenoviral TSG-6
or control luciferase expression vector. Inflammation-related protease activity
was measured using bioluminescent Prosense probes. After a second adenovirus
injection, cartilage damage was assessed in histological sections stained with
Safranin-O. Ectopic bone formation was scored in X-ray images of the affected
knees.
Results: TSG-6 did not inhibit the formation of multi-nucleated osteoclasts, but
caused a significant reduction in the resorption activity on dentin slices. Adenoviral
TSG-6 gene therapy in CIOA could not reduce the cartilage damage compared to the
luciferase control virus and no significant difference in inflammation-related
protease activity was noted between the TSG-6 and control treated group. Instead,
X-ray analysis and histological analysis revealed the presence of ectopic bone
formation in the TSG-6 treated group.
Conclusion: Gene therapy based on the expression of TSG-6 could not provide
cartilage protection in experimental osteoarthritis, but instead resulted in increased
ectopic bone formation.
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INTRODUCTION
No disease-modifying treatments are currently available for the treatment of osteoarthritis
(OA) and affected end-stage joints are often surgically replaced (Lambova, Hermann &
Muller-Ladner, 2017). OA was once viewed as mechanical wear-and-tear of the cartilage,
but in recent years there is increasing evidence that OA is a complex disease affecting
the whole joint (Malemud, 2015). Multiple proteins might interfere with OA pathology,
including tumor necrosis factor-alpha (TNFa)-stimulated protein 6 (TSG-6)
(Wisniewski & Vilcek, 2004).
TSG-6, encoded by the TNFa-induced protein 6 (TNFAIP6) gene, is glycoprotein
expressed by different cell types after inflammatory stimulation (Milner & Day, 2003).
While the protein is not detectable in healthy joint tissue, TSG-6 is present in the
synovium, cartilage, and blood vessel walls of both rheumatoid arthritis (RA) and OA
patients (Bayliss et al., 2001). In OA patients, the TSG-6 activity is associated with
disease progression (Wisniewski et al., 2014). TSG-6 protein consists of a Link and a
CUB domain that can bind multiple proteins and extracellular matrix molecules
(Milner, Higman & Day, 2006) and has protective effects in experimental arthritis
models. Transgenic mice with cartilage-specific constitutive overexpression of TSG-6
show chondroprotective, but not anti-inflammatory effects of TSG-6 in the antigen-
induced arthritis model (Glant et al., 2002). In addition, recombinant TSG-6 also showed
anti-inflammatory effects in collagen-induced arthritis (Mindrescu et al., 2000).
Correspondingly, TSG-6 deficient mice suffered increased neutrophil influx and
increased arthritis severity after induction of proteoglycan-induced arthritis (Sza´nto´ et al.,
2004). Moreover, the therapeutic anti-inflammatory effects of mesenchymal stromal
cells in a murine model for myocardial infarction were shown to be TSG-6-dependent
(Lee et al., 2009).
Several mechanisms have been proposed for the chondroprotective and anti-
inflammatory effects of TSG-6 (Milner, Higman & Day, 2006). Firstly, the Link domain
of TSG-6 can bind to many cytokines and glycosaminoglycans (GAGs), which might
prevent the migration of leukocytes to inflammatory sites (Dyer et al., 2014, 2016).
Secondly, TSG-6 can bind non-covalently to the inter-a-inhibitor (IaI) to increase its
anti-plasmin activity (Getting et al., 2002). The inhibition of plasmin may prevent the
cleavage and activation of pro-matrix metalloproteinases (pro-MMPs) to protect the
cartilage. In addition, TSG-6 has been shown to bind to BMP-2 and RANKL which
reduced osteoclast activity, but not osteoclast differentiation (Mahoney et al., 2008, 2011).
Because cartilage damage, inflammation and bone remodeling have also been
implicated in the pathogenesis of OA, we hypothesized that TSG-6 gene therapy might
also have protective effects in experimental OA. In this study we first showed functionality
of the TSG-6 gene therapy in vitro by inhibiting osteoclast activity. Subsequently, we
tested the TSG-6 gene therapy in the collagenase-induced OA (CIOA). We did not
observe therapeutic effects of TSG-6 overexpression on inflammation or cartilage damage.
In contrast, we observed ectopic bone formation at the medial femur/tibia region of
the joint.
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MATERIALS AND METHODS
Virus production
For cloning of the third generation self-inactivating lentiviral vector (sin), the full-length
TSG-6 coding sequence was obtained from a cDNA sample of inflamed synovium of
a C57BL/6 mouse by nested PCR. The first round of PCR was done by amplification
using forward primer 5′-CGGCTCTGCAACCGAAGA-3′ and reverse primer 5′-
ATCCAAAAGTATTTATTACAGCAAT-3′. For the second round of amplification,
forward primer 5′-GTCGACGCCACCATGGTCGTCCTCC-3′ and reverse primer 5′-
CATATGATCCAAAAGTATTTATTAC-3′ were used, introducing restriction sites for SalI
and NdeI, respectively, after which the TSG-6 gene was cloned in the PCR-script CAM
cloning vector (Agilent Technologies, Amstelveen, Netherlands) according to the
manufacturer’s protocol. Subsequently, the TSG-6 gene was cloned in the pRRL-cPPT-
PGK-luc-PRE-SIN vector (PGK-TSG6) using the strategy previously described
(Broeren et al., 2016). As a control vector (PGK-luc), the Trifusion reporter gene was
digested from the pcDNA3.1 vector (kind gift from Robert E. Reeves, Stanford University)
using NheI and XbaI (New England Biolabs, Ipswich, MA, USA). For adenovirus cloning,
TSG-6 was digested from the PCR-script CAM vector using SalI and ligated in the SalI
pre-digested pShuttle-CMV (Stratagene, La Jolla, CA, USA) (CMV-TSG6). The CMV-
luciferase adenovirus (CMV-luc) was used as control vector. Lentiviral and adenoviral
vector production were performed as described previously (Blaney Davidson et al., 2007;
Broeren et al., 2016).
Bone marrow-derived cell culture
Bone marrow-derived cells (BMDCs) of C57BL/6 mice were obtained from the femur
and the tibia. Bone marrow cells were flushed from the bones using RPMI medium
supplemented with 10% fetal bovine serum (FBS), 1 mM pyruvate and 1% penicillin/
streptomycin (P/S) using a Microlance 3 needle (Becton Dickinson (BD), Breda, The
Netherlands). Cells were passed trough a 70 mm cell strainer (Corning, NY, USA) and
centrifuged for 5 min at 1,500 rpm/423 g in a Heraeus Megafuge 16R (Thermo Scientific,
Waltham, MA, USA). In a 96-well plate (Greiner Bio-one, Alphen a/d Rijn, The
Netherlands), 105 cells/well were seeded on the surface of the plate for differentiation
analysis or on an elephant dentin slice for the bone resoption assay. Osteoclast
differentiation was induced in alpha-MEMmedium, supplemented with 5% FBS, 1% P/S,
30 ng/ml murine M-CSF (R&D systems, Oxford, UK) and 20 ng/ml soluble murine
RANKL (R&D Systems, Oxford, UK). For tartrate resistant acid phosphatase (TRAP)
staining, after 72 h the the osteoclast medium was replaced to induce osteoclast fusion with
or without 1 mg/ml recombinant murine TSG-6 (rmTSG-6) (R&D Systems, Oxford, UK)
for 24 h. Subsequently, cells were fixed and stained with the TRAP staining kit (Sigma-
Aldrich, Zwijndrecht, The Netherlands) according to the manufacturer’s protocol. For the
bone resorption assay, after 72 h the differentiation medium was replaced and cells were
transduced with 166 ng lentivirus per 105 cells in each well or left untreated until day 4, at
which an optimal dose 1 mg/ml rmTSG-6 (based onMahoney et al., 2008) was added to the
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rmTSG-6 group to align with protein production in the TSG6-transduced cells. At day 7,
medium was removed from all dentin slices. Subsequently, the cells were lysed with H2O.
Bone resorption assay
After incubation with the osteoclasts, dentin slices were incubated with 10% NH3 and
sonicated for 20 cycles 30 s on/off on a Bioruptor Next-gen (Diagenode, Seraing, Belgium)
at “high” intensity. After washing, the slices were incubated for 10 min with 10% KAl
(SO4)2 and stained with PhastGel Blue R-350 coomassie tablets (GE Healthcare,
Eindhoven, The Netherlands) according to the manufacturer’s protocol. For the
quantification, five pictures at 200 magnification were taken from every dentin slice
using the Labovert FS (Leitz, Leica, Rijswijk, The Netherlands). The Leica application
Suite (LAS) was used to analyse the average bone resorption percentage per dentin slice.
Synovial biopsy culture
Synovial biopsies were obtained from surplus C.B-17 mice after sacrifice. Using a 3 mm
biopsy punch (Stiefel, Wachtersbach, Germany), synovial explants were obtained and
combined from the lateral and medial synovium. The biopsies were kept in 200 ml RPMI
medium supplemented with 1 mM pyruvate and 1% P/S and 107 infectious units
adenovirus CMV-luc or CMV-TSG6 was added. After 2 h, 20 ml FBS was added and after
24 h, total RNA was isolated using 500 ml Tri reagent (Sigma-Aldrich, Zwijndrecht, The
Netherlands) according to the manufacturer’s protocol and processed and analyzed as
described below.
RNA isolation and qPCR
Synovial biopsies in Trizol were first homogenated using Magnalyzer Green Beads
(Roche Life Sciences, Almere, The Netherlands) and processed according to the provided
protocol. DNA was removed by DNAse and cDNA was generated using Moloney
murine leukemia virus reverse transcriptase, 0.5 mg/ml oligo(dT) primers and 12.5 mM
dNTPs (Thermo Scientific). Quantative real-time PCR was perfomed as previously
described (Broeren et al., 2016) using forward primer 5′-CAACCCACATGCAAAGGAG-3′
and reverse primer 5′-TACTCATTTGGGAAGCCCG-3′.
Collagenase-induced OA
A total of 30 female C57BL/6J mice (Janvier) of 10–12 weeks old were randomized and
housed in groups of five in filtertop cages at DM-II level with 12 h light-dark cycles and
water and standard diet (AB Diets, Woerden, The Netherlands) were provided ad libitum.
The mice received an intra-articular (i.a.) injection of 107 infectious units adenovirus
CMV-luc or CMV-TSG6 dissolved in 6 ml 0.9% NaCl four days prior to the start of the
induction of the model. All i.a. injections were performed during the day in the right knee
using a BD microlance needle 30G 1/2′ (BD) under general anaesthesia using 2.5%
isoflurane. The injections were performed by a technician without knowledge of the
viral vector content in a laminar flow cabinet. CIOA was induced by two i.a. injection
of one unit collagenase type VII (Sigma-Aldrich, Zwijndrecht, The Netherlands) in
6 ml 0.9% NaCl at day 1 and day 3 as described previously (Schelbergen et al., 2015).
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At day 21, a second injection of 107 infectious units adenovirus of the same viral vector
was given and mice were sacrificed by cervical dislocation at day 42. All animal
experiments were approved by the local authority Animal Care and Use Committee and
local ethics committee (RU-DEC 2014-080). Animal care was in accordance with the
institution guidelines.
Prosense measurement
Six days after the first collagenase injection, five mice per group received i.v. injections
of 1.33 nmol Prosense 680 probes (PerkinElmer, Groningen, The Netherlands) in 100 ml
in the orbita plexus. At day 7, hair was removed from the knees and the mice were
imaged with the IVIS Lumina (PerkinElmer, Groningen, The Netherlands) using the
Cy5.5 filter. The data was analyzed using Living Image 3.0 (PerkinElmer, Groningen,
The Netherlands). Regions of interest of the same size were drawn around the knees and
the florescence intensity were determined for the experimental and contralateral knees.
X-ray imaging
After sacrifice, the mouse knees were removed and imaged using the Faxitron FX-20
(Faxitron, Tucson, AZ, USA) at 26 kV for 10 s. The images were blinded and randomized
and the ectopic bone formation was given an arbitrary score of 0–5. 0 = No ectopic
bone formation visible, 1 = ectopic bone formation just detectable, 2 = clear ectopic bone
formation, 3 = bone formation stretching along femur and tibia, 4 = large ectopic
bone formation, 5 = severe ectopic bone formation, similar to the most severe sample.
Histological analysis
After X-ray imaging, knee joints were fixed in formalin, embedded in paraffin and cut
in 7 mm sections. The sections were stained with Safranin-O/Fast Green, blinded and
randomized. Cartilage damage was assessed using an arbitrary score of 0–30 based on
the OARSI cartilage OA histopathology grading system (Pritzker et al., 2006), modified for
the assessment of murine knee joints by scoring the staging 0–5. Several mice showed
dislocation of the knee joint, but these were distributed equally between the groups
and are incorporated in the analysis.
Statistical analysis
Statistical comparisons were performed by one-way analysis of variance (ANOVA) and
Mann–Whitney U test as indicated in the text using GraphPad Prism 5.03. Results are
depicted as mean ± 95% confidence interval (CI) and p-values below 0.05 were regarded
as significant.
RESULTS
TSG-6 inhibits osteoclast activity
An increase in TRAP-positive osteoclasts is observed in the subchondral bone of OA
patients (Prieto-Potin et al., 2015). We therefore first tested the functionality of viral
expression of TSG-6 in vitro by assessing its effects on osteoclast activity. BMDCs were
differentiated to multinucleated osteoclasts using M-CSF and RANKL in the absence
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or presence of recombinant murine TSG-6. The formation of multi-nucleated osteoclasts
from BMDCs was observed in conditions with and without TSG-6 (Fig. S1).
We subsequently assessed the effects of TSG-6 on osteoclast resorption activity on
dentin slices. Under positive control conditions with lentiviral control virus, resorption
pits covered ∼20% of the dentin surface (Fig. 1). The resorption by the multinucleated
osteoclasts was significantly reduced by both recombinant TSG-6 (∼72%) and the
lentiviral expression of TSG-6 (∼49%). No statistical difference was observed between the
effects of recombinant TSG-6 and lentivirus-expressed TSG-6 This shows that viral
overexpression of TSG-6 can result in functional levels of TSG-6 that can inhibit osteoclast
activity.
Overexpression of TSG-6 in synovium was first investigated in synovial explants. After
transduction with adenoviral CMV-TSG6, the expression of TSG-6 was significantly
increased compared to CMV-luciferase (Fig. 2A).
TSG-6 effects in CIOA
The protective effects of TSG-6 on inflammation and cartilage damage were tested in the
CIOA model, an experimental OA that includes inflammation (Schelbergen et al., 2015).
Mice received an injection with adenovirus to provide high expression levels of TSG-6
or control luciferase in the right knee four days prior to the first collagenase injection.
Figure 1 Bone resorption by bone marrow-derived cells (BMDCs) after TSG-6 treatment. BMDCs
were seeded on dentin slices and differentiated to osteoclasts. After three days of differentiation, cells
were transduced with control of TSG-6 virus or not transduced. After 24 h, 1mg/ml recombinant murine
TSG-6 (rmTSG6) was added to the rmTSG-6 group The cells were incubated for three additional days
and thereafter the resorption pits were evaluated. RANKLwas present during the whole experiment, but
was omitted in the “no RANKL” group. Every sample represents an average of five pictures and the bone
resorption is depicted as percentage resorption of the complete surface. The results are representative for
multiple experiments and values are depicted as mean ± 95% confidence interval (CI). Statistical
comparisons were performed by one-way ANOVA. Full-size DOI: 10.7717/peerj.4771/fig-1
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The effects of TSG-6 on inflammation-associated protease activity was determined in a
subset of the mice after injection of Prosense 680 probes at day 6 after the first collagense
injection. At day 7, the fluorescence intensity was measured and compared to the naı¨ve
contralateral knee. No significant differences in protease activity were found between the
TSG-6 adenovirus (average 2.0-fold compared to contralateral joint) and the luciferase
control virus (average 1.6-fold compared to contralateral joint) (Fig. 2B). A second
adenovirus injection was given at day 20 to provide TSG-6 expression for the second
half of the model and mice were sacrificed at day 42. The cartilage damage was assessed
in histological sections using the OARSI cartilage OA histopathology grading system.
No significant differences were observed in cartilage damage between the control group
and the TSG-6 treated group (Figs. 2C–2E).
Before the joints were processed for histological analysis, the bone structure was
analyzed using X-ray imaging and scored using an arbitrary scoring method from
0 to 5. Surprisingly, mice treated with adenoviral TSG-6 showed significantly more
ectopic bone formation (77%) compared to the control group (20%) located at the medial
collateral ligament (Figs. 2F–2H). Safranin-O staining of histological sections of the
joints shown in Figs. 2F and 2G shows the presence of cartilage around the ectopic bone,
indicating that the ectopic bone formation might be the result of endochondral
ossification (Figs. 2I and 2J).
DISCUSSION
In this study, we show that in vitro viral overexpression of TSG-6 in BMDCs has no effect
on multinuclear osteoclast formation, but can reduce resorption activity of the
osteoclasts. This has been observed in earlier studies (Mahoney et al., 2008, 2011) and
shows that functional TSG-6 can be expressed after viral gene transfer and reduce in vitro
bone resorption. However, when tested in the CIOA model, TSG-6 could not reduce
cartilage damage. In contrast, we observed increased ectopic bone formation in mice with
TSG-6 overexpression.
The lack of protective effects from TSG-6 overexpression on the development of
cartilage damage, despite the inhibitory effects on osteoclast activity, might be related
to the indications that cartilage damage in the CIOA model is caused by mechanical
stress resulting from joint instability (van der Kraan et al., 1990). Mechanical stress
is implicated as an important cause for cartilage damage in many OA patients
Figure 2 Effects of adenoviral luciferase or TSG6 on collagenase-induced osteoarthritis (CIOA) in n = 15 mice/group. (A) Expression of TSG-6
in synovial explants, 24 h after transduction with adenoviral CMV-luciferase (CMV-luc) or CMV-TSG6. (B) Prosense measurement at day 7 to
assess the inflammation-associated protease activity in a random n = 5 subset/group. The fluorescence intensity ratio compared to the contralateral
knee was calculated. (C, D) Magnification of examples of cartilage damage. Representative pictures of the medial femur and tibia are shown after
Saphranin-O staining (average cartilage damage score 14). The scale bare indicates 200 mm. (E) Cartilage damage at day 42. For every knee joint, the
cartilage damage was determined in the medal tibia, medial femur, lateral tibia, and lateral femur in three sections. The average cartilage damage
is depicted. (F, G) Typical X-ray images of knee joints at 42, score 0 and 5, respectively. Ectopic bone formation is indicated by the red arrow.
(H) Arbitrary scoring of ectopic bone formation (0–5) in the X-ray images. (I, J) Histological sections of the knee joints shown in Fig. 2E. Sections
were stained with Safranin-O and counterstained with Fast Green. Ectopic bone formation is indicated with black arrows. Quantitative results are
depicted as mean ± 95% confidence interval (CI) and statistical comparisons were performed by Mann–Whitney U test.
Full-size DOI: 10.7717/peerj.4771/fig-2
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(Guilak, 2011; Buckwalter et al., 2013), but is distinct from the mechanisms that cause
cartilage damage in the RA models in which TSG-6 treatment was successful.
Although TSG-6 is associated with different functions that might be protective for
OA, the expression and activity of TSG-6 correlate with progression of OA (Wisniewski
et al., 2014). The exact mechanisms by which TSG-6 might be involved OA progression
is not completely understood and is difficult to study because of the ability of TSG-6 to
bind many different proteins and matrix components. Thus, TSG-6 may have tissue-
specific functions, resulting in protective effects in experimental RA, but detrimental
effects in OA models. One potential mechanism could be related to a disturbance of
damage repair mechanisms. TSG-6 has been shown to bind to fibronectin (FN),
stimulating FN matrix assembly involved in damage repair (Kuznetsova et al., 2008).
However, TSG-6 can also serve as a bridging molecule between FN and thrombospondin-1
(TSP-1). TSP-1 is increased in OA chondrocytes and osteophytes and has multiple
functions, including the activation of latent transforming growth factor-b (TGF-b)
(Crawford et al., 1998; Pfander et al., 2000). Increased TGF-b activity has previously been
correlated with chondrocyte differentiaton and enthesophyte formation similar to this
study in the medial collateral ligament in CIOA (Blaney Davidson et al., 2007; de Munter
et al., 2013). The formation of osteophytes in these marginal locations is associated
with OA progression in human OA (Felson et al., 2005).
An alternative mechanism for increased TGF-b activity could be related to hyaluronan
(HA). In the context of fibrosis, studies have shown that the heavy chain transfer to HA by
TSG-6 can stabilize the HA coat, which is essential for TGF-b-mediated myofibroblast
differentiation (Meran et al., 2013). Possibly, TSG-6 can increase TGF-b-mediated
chondrogenesis in a similar way. HA could also increase chondrogenesis in adipose-
derived stem cells (Wu et al., 2013). This was dependent on the interaction between
HA and CD44, which is influenced by TSG-6 (Lesley et al., 2004). The formation of
bone is dependent on the ratio between bone matrix deposition and bone resorption.
The inhibiting effects on osteoclast activity observed in Fig. 1 might favor the anabolic
activity and stimulate the ectopic bone formation. Although the exact mechanism by
which TSG-6 can increase ectopic bone formation in vivo remains to be elucidated, no
improvement in cartilage damage in was observed, indicating that intra-articular gene
therapy with TSG-6 might not be a promising treatment for OA.
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